The positive trial results for danicopan are likely to be viewed favorably by investors, as they suggest a potential new treatment option for PNH patients and an enhancement to AstraZeneca's product lineup. The premarket share price increase indicates a positive short-term impact, although the modest rise suggests that the market may have already partially priced in the expectations for successful trial outcomes.